Gail Maderis

Gail Maderis has significant experience in the biopharmaceutical industry and has held leadership roles in several companies. Gail is the President & CEO of Antiva Biosciences, Inc., a venture-backed biopharmaceutical company focused on developing topical antivirals for the treatment of pre-cancerous lesions caused by the human papilloma virus (HPV). Gail has been with Antiva Biosciences since 2015 and is currently leading the clinical trials for their lead product, ABI-2280, for the treatment of cervical neoplasias.

In addition to their role at Antiva Biosciences, Gail Maderis serves as a Board Member for DURECT Corporation, Valitor, Inc., Biotechnology Innovation Organization, CLSI California Life Sciences, The Termeer Foundation, Allarity Therapeutics, NovaBay Pharmaceuticals, and Opexa Therapeutics. Gail also holds the position of Trustee for UC Berkeley Foundation at the University of California, Berkeley.

Gail Maderis has a diverse background in the biopharmaceutical industry and has extensive experience in leadership and board positions.

Gail Maderis obtained their Bachelor of Science degree in Business Administration and Management, General from the Haas School of Business at the University of California, Berkeley. Gail attended this program from 1975 to 1978. Later, they pursued their Master of Business Administration (MBA) at Harvard Business School, completing the program from 1983 to 1985.